drugset / Trial / NCT03284866
HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV
Phase 3
Completed
536 enrolled
AIDS Malignancy Consortium
AIDS and Cancer Specimen Resource · collabMerck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collabThe Emmes Company, LLC · collabUniversity of Arkansas · collabUniversity of California, Los Angeles · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This randomized phase III trial studies how well human papillomavirus (HPV) vaccine therapy works in reducing high-grade cervical lesions in patients with human immunodeficiency virus (HIV) and HPV. Vaccines made from HPV peptides or antigens may help the body build an effective immune response to kill the HPV virus and prevent cervical lesions from developing or coming back after being removed.
Timeline
- Start
- 2019-07-31
- Primary completion
- 2024-11-26
- Completion
- 2025-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gardasil 9 | Vaccine | — | Intramuscular |